News Hub | News Direct

Minuteman Press Franchise Comes to Poundbury and Dorchester, Moves to Brand New Premises

Minuteman Press International Inc

Sprint Digital, Dorchester's leading small business printers, have successfully completed the transition into a Minuteman Press franchise. Owners David and Juanita Prince have relocated from their town centre premises, shared with the Dorchester Post Office, into their own stand alone premises in Poundbury at 13 & 14 Jubilee Court, Paceycombe Way. David Prince said, “With easy access and free parking, the offices just down from the Buttermarket are well placed for access for our clients. We will also continue to deliver to our existing business customers in Dorchester should they need to ensure a seamless transition for our clients.” Operating for over 50 years to serve local business communities, Minuteman Press International has almost 1000 independently owned and operated franchise locations worldwide. The transition from Sprint Digital to Minuteman Press will give small businesses in Dorchester, Poundbury and its surrounds more access to an extremely wide range of print solutions, from business cards and fliers to small signage, branded promotional items and much more. In response to the rebranding, David and Juanita stated, "The move to Minuteman Press will allow our print business to grow offering the businesses of Dorchester, Poundbury and its surrounds a quality affordable print solution. We are also inviting businesses to shop locally knowing that the product is as environmentally sourced as possible and supported by the expertise of world's leading print franchise.” Mark Jones, Regional VP of Minuteman Press International added, "We are excited to be working with David and Juanita, helping them to grow their franchise whilst supporting the local community with all their print requirements." As part of the conversion David Prince has reaffirmed that MMP Dorchester will take over Sprint Digital's sponsorship of the Dorchester Ladies football team into the 2023/24 season and they will continue to support the developers of Dorchesters Bike Park by providing a range of print solutions for their promotional needs. For more information on Minuteman Press in Dorchester and Poundbury, call 01305 264171 or visit their website: https://minuteman.com/uk/locations/england/dorchester/ Minuteman Press provides digital print, design, promotional products and services to businesses. Today they are much more than just print. They can provide anything you can put a name, image or logo on! Minuteman Press International was once again rated the #1 Printing & Marketing Services Franchise in the printing industry by Entrepreneur Magazine in 2023. This is the 32nd time overall and 20th straight year that they have achieved this stellar rating. Learn more about Minuteman Press franchise opportunities and read Minuteman Press franchise reviews at http://minutemanpressfranchise.co.uk Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

October 05, 2023 09:38 AM Eastern Daylight Time

Image

Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update

Benzinga

By Rachael Green, Benzinga Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, the multi-center clinical trial will have six to ten new clinical trial sites across the US. According to the Company, another key data milestone is expected soon at the ECTRIMS conference, which will detail the results from the expanded access program after six months of treatment. Investors should take note, as this is a significant event for the company through providing six-month clinical results on the second cohort of four patients (numbers 3-6), and also providing a PET scan which shows neuroinflammation in the brain (microglia). ECTRIMS is the world’s largest research meeting in multiple sclerosis and will be held October 11-13 in Milan, Italy. Tiziana also recently announced the acceptance of a publication in the prestigious journal Proceedings of the National Academy of Sciences (PNAS) of its study validating the mechanism of action (MoA) using intranasally administered foralumab in Alzheimer’s disease (AD). The published study concluded that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”, which further supports the Company’s hypothesis for the use of foralumab in neurodegenerative disease. Key highlights from the Journal included: The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s Disease The publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer’s disease by targeting microglial activation in the brain, while expanding regulatory T cells in the periphery Remarkably, this reduced microglial activation and improved cognition occurs independent of amyloid beta disposition. The full publication can be found HERE Tiziana’s Foralumab Is A Promising Treatment With Potential To Treat Multiple Neurological Diseases “The anti-CD3 target is established and it’s validated,” said Tiziana COO and CMO Mathew Davis at a recent conference. “We are the only company that is delivering this intranasally. We are the only company that is in the clinic with a fully human anti-CD3 antibody.” The anti-CD3 monoclonal antibody used in Tiziana’s Foralumab binds to the CD3 receptor on the surface of T cells, typically used as a way to suppress the immune system to prevent transplant rejection or treat autoimmune disease. The challenge in treating these kinds of conditions has long been finding the balance between suppressing the immune response to protect the patient without harming the body’s ability to fight off actual threats like viral infections and bacteria. However, research shows that anti-CD3 antibodies can do just that. They are able to selectively dampen the autoimmune response – when the dysregulated immune system attacks the body’s own cells and tissue – without limiting its ability to detect and respond to external threats. The promising new treatment approach has already sparked interest from pharmaceutical industry leaders like Sanofi SA (NASDAQ: SNY), which just acquired an anti-CD3 therapy being developed for type 1 diabetes in a $2.9 billion acquisition of Provention Bio, Inc. Tiziana’s Foralumab is the only anti-CD3 monoclonal antibody treatment in clinical trials that is fully human — a significant differentiator as these tend to come with fewer adverse reactions than those that are genetically engineered. It’s also the only one that’s delivered via an intranasal spray, making it less invasive than an infusion and allowing it to travel directly to the T cells in the patient’s lymph nodes. In the neurological diseases that Tiziana is focused on, this formulation has allowed its lead drug candidate to bind to regulatory T cells, then these T cells activate and create Tregs which are specifically tasked with maintaining homeostasis and preventing the immune system from attacking itself. Once Foralumab creates these Tregs, they can cross through the blood-brain barrier and help fight neuroinflammation at its source. Tiziana Highlights Past Results And Upcoming Milestones Across Foralumab Clinical Trials During a recent investor conference, Davis focused on the exciting results Tiziana has seen so far from its clinical trials and highlighted some of the upcoming milestones and plans for the year ahead. Its lead program is in non-active secondary progressive multiple sclerosis (SPMS), a more severe stage of the debilitating disease that currently has no FDA-approved treatment. Instead, the standard of care typically involves treating the patient with Ocrelizumab, an anti-CD20 monoclonal antibody sold under the brand name Ocrevus by Genentech, a subsidiary of Hoffmann-La Roche AG (OTCQX: RHHBY). But the drug is not always as effective for SPMS patients as it is for other forms of MS. In fact, Davis noted that all of the patients in its clinical trials had previously tried Ocrelizumab and discontinued it when their symptoms continued to progress. In its ongoing expanded access program, for example, the Tiziana COO and CMO spoke about a patient who had discontinued the anti-CD20 treatment in 2021 when his condition had become so bad that he could no longer walk more than 100 feet without assistance. The non-active SPMS patient enrolled in Tiziana’s expanded access program in January 2022. “By the end of 2022, he was able to walk without assistance,” Davis said. “He’s back in his job and, as of this recording, he continues to walk without assistance.” In the biopharma’s most recent data readout, other patients from the expanded access program started to show similar improvement. Three of the four patients currently enrolled saw their fatigue scores decrease after three months. Meanwhile, a phase 1 trial found that microglia – a part of the innate immune system inside the brain – had significantly decreased activation in the brains of 5 out of 6 treated patients after three months. Davis said another data readout is expected soon, detailing the results from the expanded access program after six months of treatment. Tiziana has begun clinical site selection and plans to start a phase 2a trial in non-active SPMS before the end of this year with topline data expected by the end of 2024. The clinical-stage biopharma is also investigating Foralumab for Alzheimer’s disease (AD), another progressive neurological disease with an urgent need for better treatment options. Tiziana just received FDA approval to begin a phase 2 study in AD, and the company plans to launch that trial in the first half of next year. A press release on the acceptance from the Proceedings of the National Academy of Sciences (PNAS) can be found HERE along with the full publication HERE titled “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”. To learn more about Tiziana, click HERE This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 05, 2023 09:15 AM Eastern Daylight Time

Lithium Craze: Comparing Arianne Phosphate To Top Companies

Arianne Phosphate

By Meg Flippin, Benzinga From powering electric vehicles to storing solar and wind energy, lithium plays a critical role in the transition to a greener world. So it’s not surprising demand for Lithium-Iron-Phosphate (LFP) batteries is exploding – as are the market values of its key publicly traded producers. With energy and food prices still high and weather-related calamities occurring far too often, everyone from companies to consumers is looking for greener alternatives across the board. Electric vehicles have driven a lot of the demand, but lithium is also used in storing captured wind and solar for the power grid and residential solar power systems. LFPs Gaining Traction For years, North American EV makers relied on lithium-ion batteries made of lithium, cobalt and nickel to power this greener vision. But cobalt and nickel are scarce and expensive – not to mention controversial. Companies looking for an alternative have turned to LFPs. These batteries are highly stable, longer lasting, and more resistant to heat degradation. They also require less lithium. In 2022, about 737,000 tons of lithium was produced globally. That’s expected to increase to 964,000 tons in 2023, reaching 1.17 million tons by 2024. The LFP market is projected to exceed $50 billion by 2023. And, in a recent report, Wood Mackenzie predicted that lithium iron phosphate will become the leading battery chemistry for EVs by 2028. Beyond EVs, there’s another big opportunity for LFPs: energy storage systems and powerwalls. These are designed to store energy from solar or the grid to be used later. Some are portable while others are connected. Tesla, Inc. (NASDAQ: TSLA) is increasingly using LFPs in its energy storage products, which bodes well for the industry. Northern Exposure Evidently, this isn’t lost on investors, and many investors are watching publicly traded lithium companies keenly. Some of the key players include Albemarle Corp. ( NYSE: ALB ), Sociedad Química y Minera S.A. (NYSE: SQM), Ganfeng Lithium Co., Ltd. (OTCMKTS: GNENF) and Mineral Resources Ltd. (OTCMKTS: MALRY). But they aren’t cheap. Albemarle currently trades at around $168 per share. In dollar terms, that’s more expensive than General Motors (NYSE: GM), Ford (NYSE: F), and even Amazon (NASDAQ: AMZN). Meanwhile, SQM sports a $15.85 billion market valuation. Fortunately, there are cheaper ways to get exposure to the lithium battery market, such as through the miners that provide the minerals needed to make batteries. Arianne Phosphate (OTCMKTS: DRRSF), one such company hailing from Quebec, Canada, provides a key ingredient for LFP batteries and is cheaper than the aforementioned lithium stocks in dollar terms. But, as its phosphate is snapped up by producers of everything from EVs to solar storage systems, that may not be the case for long. Deposits Set it Apart Arianne’s Lac à Paul project in Quebec could become a key resource for manufacturers. The geology of the deposit is igneous and thus very rare, with less than 10% of all phosphate coming from ore bodies of this nature. Arianne’s deposit can produce a purer concentrate, higher than over 90% of the world’s phosphate. Further, aside from the phosphate content, Arianne reports that its deposit does not have any issues with deleterious elements (radioactive, heavy-metal) that are found in most of the world’s phosphates. From an ESG perspective, Arianne’s mine also adheres to strict environmental, social and corporate standards that set it aside from most other deposits. There is also pro-mining legislation that helps companies like Arianne. The White House’s American Battery Materials Initiative is aimed at securing a reliable and sustainable supply of critical minerals used for power, electricity, and EVs. Meanwhile, the Department of Energy is awarding $2.8 billion from the Bipartisan Infrastructure Bill to boost domestic manufacturing. Lastly, Quebec has shown itself to be aggressive in attracting and advancing battery initiatives and is expected to play a significant role in Arianne’s advancement. Judging by how the market is moving, LFPs could well be the future. A cheaper way to play this exploding market is with phosphate, of which Arianne appears to be a well-positioned producer. ARIANNE PHOSPHATE INC. ( www.arianne-inc.com ) owns the Lac à Paul phosphate deposit in Quebec, Canada. Fully permitted and shovel ready, the asset is among the world’s largest greenfield deposits, capable of producing an environmentally friendly phosphate concentrate. Due to the nature of its high-purity, low-contaminant product, Arianne’s phosphate can be used to produce fertilizer as well as meeting the technical requirements of specialty applications such as the lithium-iron-phosphate (LFP) battery. The Lac à Paul deposit is rare due to its geographic location and geological structure. Arianne Phosphate is listed on both the TSX-V: DAN and the OTCQX: DRRSF. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. This information contains forward looking statements. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding potential mineralisation and reserves, exploration results and future plans and objectives of Arianne Phosphate Inc, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Arianne Phosphate Inc’s (“Arianne Phosphate” or the “Company”) expectations are disclosed under the heading "Risk Factors" and elsewhere in Arianne Phosphate Inc’s documents filed from time-to-time with the TSX Venture and other regulatory authorities. Contact Details Brian Ostroff, President brian.ostroff@arianne-inc.com Company Website https://www.arianne-inc.com

October 05, 2023 09:15 AM Eastern Daylight Time

Are You Trading With Or Against the Market Makers?

TechniTrader

Most retail traders blame the Market Makers for their losses. The reality is that you are often trading against a Market Maker rather than with the trend of the market. To provide some background, I’ll give you a synopsis of one of my personal experiences with Market Makers. Many years ago, I walked into our trading offices to see my business and trading partner, Howard, on the phone laughing and joking as if it was his best buddy. He quickly jotted a note to me. I read it and jolted. “The Market Maker?” I whispered. He grinned. I was speechless. My trading partner was talking to a NYSE Market Maker during trading hours. How he managed that I will never know. After the conversation ended, Howard explained that he wanted to make sure that what we were going to teach in our first ever 2-day workshop was consistent with Market Maker strategies. The Market Maker not only thought that Howard’s new order type was brilliant, he asked if he could use it on his trading floor. I was more concerned that everybody already knew what we were teaching. But that worry dissipated 10 minutes into my live training in a room packed with professionals, retail day traders and retail investors. That was over 25 years ago. We still use that unique order type today for teaching students, both retail and professional traders. There have been a few minor tweaks but it still works amazingly. Howard’s novel order entry method is still being used by professionals today. There are other stories, but for now let’s talk about Market Makers. The Stock Market of the USA guarantees only ONE thing: for every buyer, there will be a seller and for every seller, there will be a buyer. That’s it. No promise of great, instant wealth. No promises of getting rich quick. When you trade, you need to understand the role of the Market Maker. The stock market is not a casino, it is a giant auction that Market Makers facilitate. There are 3 types of Market Making in today’s market structure: 1. Automated, Computer-Generated Make the Market Systems. The US exchange computers adjust the pricing of every US listed stock before the US stock market opens on the East Coast of the US at 9:30 ET. The goal of adjusting the pricing structure seconds ahead of open is to prevent any arbitrage between global stock markets for retail investors and retail traders. This is a fully automated system that has minimal human intervention. 2. HFT Maker/Takers and HFT Market Makers. High Frequency Trading, aka HFT, is automated programs that generate huge volumes of small-lot orders on the millisecond scale that convert to larger orders on the retail side's one-minute scale. HFTs have been part of the market since 2002. HFT algorithms are set up by humans but the orders are fully automated. The role of these HFTs is to provide liquidity to the exchanges. Illiquidity is a major problem for the exchanges. This is because of the Dark Pools, which are Alternative Transaction System (ATS) venues. About 80% of all liquidity is off the exchanges in ATS venues. In the past few years, the major exchanges have opened up ATS venues to ensure they have sufficient revenues. So they have become quite huge. 3. Major Banks and Giant Financial Services Companies Approved for Market Making. JP Morgan Chase, Goldman Sachs, Citadel (also the largest PFOF, Payment for Order Flow market maker–retail orders are sent to them from retail brokers) are the prominent Market Makers at this time. There are others, of course. They have huge trading floors with the most experienced, savvy and skilled traders in the world. Making the Market is required during stressed market conditions, when there is a VOID of buyers. Recently, the market has encountered a VOID of buyers. This is not illiquidity, it is not volatility, it is an absence of major market participant groups buying. The lack of buyers creates a void, an absence of buyers, which are necessary to complete order transactions. Market Makers fill that role by setting up Sell Short Orders at appropriate price levels for that day’s open based on overnight order flow data from retail brokers. When there is a void of buyers, Market Makers use short orders, which can be canceled automatically if conditions change, and then establish the buy-to-cover price. This is based upon technical and fundamental data in a graphical chart format. The orders are then automated to trigger as the market opens. IF you are chasing HFTs trying to sell short, you will lose money. The HFTs start buying to cover their short trades as soon as the stock gaps down at open. IF you are buying or selling ahead of the market open and you have not done your due diligence in determining the current Market Condition, which is a Platform Market Condition, you will lose money. (There are 6 major conditions.) Market Makers are not watching for your 100- to 1000-share order or stop loss to take you out and then smile about it. There are 30 – 40 million transactions every day in the US stock market. The reason you are losing money is because you are unaware of what is happening on the professional side of the market. You are trading against the professionals. How to solve this problem? Find trading education that helps you understand how the professionals trade. Look for a methodology that shows you how to identify their activity with the tools you already have. Visit my website to learn more about my unique approach to reading charts: Relational Technical Analysis. Martha Stokes, CMT https://www.technitrader.courses/ TechniTrader has been teaching traders and investors a complete process for trading or investing in the stock market and other financial markets since 1998. We have helped over 500,000 traders and investors achieve their financial goals. Our courses provide a complete, comprehensive training program based on a college-style curriculum that uses a tri-level approach to analyzing assets or derivatives to trade. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Mel Ainuu mel@technitrader.com Company Website https://www.technitrader.courses/

October 05, 2023 09:15 AM Eastern Daylight Time

Interactive Strength Works To Sign Binding Acquisition Agreement That Would Transform The Digital Fitness Company Into A Profitable, High-Growth Business Across B2B and B2C Markets

Benzinga

By Rachael Green, Benzinga Interactive Strength, Inc. (NASDAQ: TRNR), doing business as FORME, is currently working towards signing a definitive agreement to acquire a connected hardware “target” after announcing a non-binding letter of intent last month. The combined Company is projected to generate $10 million in 2023, more than $25 million in gross revenue in 2024, and is expected to be cashflow positive and adjusted EBITDA profitable by the fourth quarter of 2024. The potential transaction is expected to accelerate FORME’s commercialization path, result in immediate scale across all functions and create a high-growth and profitable platform that sells connected hardware/software fitness platform across B2B and B2C channels. The premium smart home gym and virtual personal training provider is aiming to execute a definitive acquisition agreement by the fourth quarter of this year. Here are some of the growth opportunities investors can look for as FORME works toward a binding agreement by the end of this year. The Potential Acquisition Would Create A Significantly Scaled Up Connected Fitness Equipment Business “We believe this will be a transformational acquisition that can accelerate our commercialization path,” said FORME Founder and CEO Trent Ward. “We expect this transaction can help us achieve immediate scale across all of our cost centers, resulting in a high-growth, profitable platform that sells connected fitness equipment and digital fitness services across B2B and B2C channels.” In addition to scaling FORME’s sales, engineering, logistics and other functions, the connected fitness acquisition would be a synergistic merger that would immediately create cross-selling opportunities across both FORME’s and the target’s customer base. It also has the potential to bring in a strong B2B distribution partner for FORME’s premium smart home gym equipment, allowing FORME to ramp up its commercialization efforts. Combined, FORME and the target acquisition are projected to bring in over $10 million in gross revenue for 2023 and over $25 million in for 2024, achieving both positive cash flow and positive adjusted EBITDA by the fourth quarter of next year. The Upside Potential Of FORME’s Transition To A B2B-Led Platform Right now, FORME primarily targets the B2C market, offering smart home gym equipment and a variety of virtual personal training plans directly to consumers. But as the rapid decline of Peloton (NASDAQ: PTON) suggests, that home fitness market just isn’t big enough to sustain long-term growth as post-pandemic consumers return to the gym. Peloton recently reported net losses of over $241 million for its fourth quarter, as sales and subscriptions continue to decline. FORME has a differentiated market strategy that addresses changing consumer habits and developed a flexible approach to its B2C segment. The Company offers both premium equipment and a range of monthly subscription options at different price points that offer live one-on-one coaching with a personal trainer through the user’s connected fitness mirror or their mobile device. But its biggest growth opportunity comes from its pivot into the B2B space, delivering its equipment and services to hotels, gyms and other enterprise customers that want to offer premium fitness options to their customers. FORME has already made some moves in this B2B channel but the potential acquisition, which is said to derive most of its sales from the B2B space, would dramatically increase its exposure to that more profitable, more scalable market. This would allow FORME to become a B2B-led platform while still maintaining and growing its B2C channel, potentially sidestepping the profitability challenges faced by Peloton and other B2C-focused companies in the connected fitness space. In an August report on FORME, Goldman Small Cap Research calls the digital fitness platform “a rare, high growth, low valuation firm offering significant upside potential.” Goldman cited the potential acquisition slated for the fourth quarter as well as the opportunity for similar deals in the future as FORME targets other acquisitions over the next few years. To watch a video with the product in action, CLICK HERE This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 05, 2023 09:15 AM Eastern Daylight Time

How one fintech solution provider is bringing change to the volatile housing market in the U.K.

Prodigy Press Wire

Pfida, a fintech company pushing for social impact, has developed their system to help people purchase homes without falling into debt and without being charged interest. Pfida’s home financing offer is a partnership-based system in which people can purchase a home, interest free and debt free. This system has been designed to bring stability to the housing market in the United Kingdom and service the most financially excluded groups hoping to explore home ownership options. Their home finance product provides users with the ability to act as partners with Pfida by putting in a minimum of 15% deposit towards the property, which then becomes the purchaser’s equity. Raza Ullah, Founder and CEO of Pfida According to Raza Ullah, Founder and CEO of Pfida, one of the reasons that housing prices in the U.K. are so high is due to inflation in the economy caused by the constant printing of money. With the savings account offering that Pfida provides, their customers can receive competitive returns on their savings without any interest rates and earn a profit share from Pfida. This enables the company to build the capital needed to offer their home finance offerings. Additionally, Pfida offers several benefits to their customers such as an equity buffer feature and potential rental discounts. The fintech also gives homebuyers the ability to pay more towards the purchase of equity, all through the online dashboard and without any additional charges. The home financing system that Pfida has developed is intended to end the cycle of debt, which according to Raza is unavoidable when dealing with a traditional mortgage. He says the current monetary systems in place throughout the U.K. have caused mass inequality between the rich and the poor. It causes people to take on large amounts of debt and get stuck trying to pay it off, which in turn leaves them unable to save money. “Our business is entirely for the people, so there’s no venture capitalists or anything like that, it’s all community funded. It’s people believing in our mission and many of them have put their hard earned savings into the business to help others buy homes with no debt or interest rates,” says Raza. Pfida Logo According to Raza, one of the top priorities for Pfida is to show the world there is a more ethical and sustainable way of financing homes for people to buy. To accomplish this, Pfida strives for customer awareness about the alternative options they offer. Additionally, Pfida hopes to influence other financial institutions to adopt similar services, allowing the world to experience the positives of an equitable and fair housing market. Raza understands this requires much time and effort to bring tangible impacts, but the Pfida team is invested in doing so. Since Pfida is an organization focused on creating social impact, without seeking people who are looking for the highest returns on their investments. Attracting people who align themselves with the social causes that Pfida is pursuing will enable the company to raise purpose-led capital through their savings accounts. Coming from a financial services background, Raza had a life-changing experience in 2016. During his pilgrimage to Mecca, he had the realization that with his skillset he needed to do something for the housing market in the U.K., which he says is currently suffering from inflation and high interest rates. He gave up the current job he held and set off to help at least one or two families avoid acquiring debt when purchasing a home. The very first property that was financed through Pfida was out of Raza’s life savings, and that's a decision he doesn't regret. “I never could have imagined at the beginning that we would grow to a team of 42 plus, and we're expecting to be around 60 by the end of the year, and serving as many customers as we have has been one of the most rewarding experiences of my life,” says Raza. “It's all about genuinely just trying to help people into homes without that death grip of debt around their neck.” Media Contact Name: Kaynat Choudhury Email: Marketing@Pfida.com Release ID: 762361

October 05, 2023 09:00 AM Eastern Daylight Time

Image

ToolsGroup Announces New User Interface for Enhanced User Experience and Supply Chain Performance

ToolsGroup

ToolsGroup, a global leader in retail and supply chain planning and optimization software, is announcing the launch of a dramatically improved user experience for its industry-leading Service Optimizer 99+ (SO99+) supply chain planning solution. SO99+ release 8.62 introduces a sleek and modern interface, incorporating the latest UI/UX design principles. This reflects ToolsGroup’s continued commitment to creating products that are intuitive and user-friendly, leading to greater adoption and improved business performance. With a clean, sophisticated interface and feature enhancements, SO99+ aligns the latest software design trends with user requirements to elevate the user experience. While familiar favorite capabilities remain – including personalized dashboards and custom alerts – ToolsGroup has also added important new capabilities to SO99+ in this release, such as enhanced seasonality clustering and aggregate forecasting functions. The latest enhancements make it easier than ever for companies to leverage machine learning, streamline processes, and maximize efficiency, empowering teams to make better, faster planning and execution decisions. “At ToolsGroup, we pride ourselves on our close collaboration with our customers, gathering their input to continuously improve our product so that we can empower users to navigate the supply chain,” said Sahil Gupta, Chief Product Officer. “This refresh of our user interface is the result of deep conversations with the people who work closely with our software to plan on a day-to-day basis and the latest trends in modern web design. Ultimately, our goal is to deliver AI-powered supply chain solutions that are easy to use – as this is how modern users are best able to drive business results.” “Our customers rely on SO99+ every day to drive the supply chain decisions that power enhanced business performance and customer experience. We have been eagerly anticipating the new user interface and look forward to imminently implementing a wealth of enhanced capability,” said James Triggs, Managing Director at Brookes Supply Chain Solutions. “We’re thrilled to collaborate with such a dynamic and technologically innovative supply chain technology partner that we have in ToolsGroup.” Watch ToolsGroup’s new SO99+ product video for a first look at the enhanced interface HERE. About ToolsGroup ToolsGroup’s innovative AI-powered solutions enable retailers, distributors, and manufacturers to navigate through supply chain uncertainty. Our retail and supply chain planning suites empower a new level of intelligent decision making and unlock powerful business improvements in forecast accuracy, service levels, and inventory - delighting customers and achieving financial and ESG KPIs. Stay in touch with ToolsGroup on LinkedIn, Twitter, YouTube, or visit www.toolsgroup.com. Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.toolsgroup.com

October 05, 2023 09:00 AM Eastern Daylight Time

Image

Navidar Advises Nova Hydraulics, Inc. in Its Sale to Motion & Control Enterprises

Navidar

Navidar is pleased to announce that our client, Nova Hydraulics, Inc. (“Nova”), has been acquired by Motion & Control Enterprises (“MCE”), a portfolio company of Chicago-based private equity firm Frontenac. Headquartered in Indianapolis, IN, Nova is an independent hydraulics solutions provider, specializing in the repair, remanufacture and supply of hydraulics parts to end-users, resellers, repair houses, and OEMs. “Navidar was instrumental at every stage of this transaction. Their team’s well-run process, ability to get up to speed quickly, and invaluable counsel were pivotal in ensuring successful outcome” said Greg Christy, Founder, Nova Hydraulics, Inc. “It was a pleasure to work with Navidar and I am delighted to have selected them as my trusted financial advisor." “Nova’s stellar reputation among industry peers is a testament to the hard work and customer-focused approach Greg and team have created,” said Stephen Day, Managing Director at Navidar. “We are grateful to have had the pleasure of advising Nova on their strategic sale to MCE who we believe will be an excellent long-term partner to Nova’s employees, suppliers, and customers. MCE’s compelling vision and customer value proposition ensures continued success and growth for all of Nova’s stakeholders.” About Nova Hydraulics Nova Hydraulics, Inc. is a hydraulics solutions provider specializing in the repair, remanufacture, and supply of hydraulic parts to end-users, resellers, repair houses and OEMs. For more information, please visit www.novahydraulics.com. About Navidar Navidar Holdco LLC (“Holdco”), with a presence in Austin, Atlanta, Cleveland, Dallas, Denver, Indianapolis, Minneapolis and San Antonio, is an investment banking firm that provides strategic merger and acquisition advice, capital raising solutions, and corporate advisory services to businesses and investors in dynamic industries. The firm focuses on SaaS software, eCommerce & Internet, information technology services, specialty manufacturing, and health care information technology companies. Navidar principals have completed more than 400 transactions representing nearly $110 billion in M&A and capital raising, for both private and public companies, over the past 20 years. Navidar Group LLC, an affiliate of Holdco, is a broker-dealer that is registered with FINRA and SIPC. Contact Details Chelsey Gonzales +1 512-765-6976

October 05, 2023 08:00 AM Central Daylight Time

Big Tech is Going Nuclear to Power AI

MarketJar

As artificial intelligence continues to revolutionize industries, there's one crucial aspect that remains largely under the radar: power consumption. Training advanced AI models, especially large language ones, demands a staggering amount of electricity. So much so, that the carbon footprint of these data-intensive tasks rivals that of entire cities. Which is why some of Silicon Valley’s most elite are turning to nuclear power as a solution to cutting carbon emissions and weaning the world off Russian gas. A recent job posting reveals that Microsoft is planning to grow its energy infrastructure by using small modular reactors (SMRs) to fuel the immense data centers driving Microsoft Cloud and AI. This isn’t the first time Microsoft has delved into the nuclear realm. In 2008, Bill Gates founded leading nuclear innovator TerraPower, which has since been meticulously crafting designs for these very SMRs. Of course, Microsoft is far from the only Silicon Valley juggernaut acknowledging the promise of nuclear energy. Billionaires Jeff Bezos, PayPal and Palantir co-founder Peter Thiel and OpenAI founder Sam Altman have also been investing big in nuclear. Helion Energy, backed by Thiel, recently secured a staggering $500 million in funding, aiming to develop a groundbreaking nuclear fusion system by 2024. Altman also recently provided funding and assumed the role of chairman at Oklo, a company dedicated to commercializing nuclear energy through the production of small, mass-manufactured reactors. These individual commitments tell only part of the story. Last year alone, investors poured a record $3.4 billion into nuclear startups, eclipsing the total investments made over the previous decade. Nuclear-related deals have also jumped significantly over the last 10 years from fewer than 10 annually to 28 in 2021. The higher demand for uranium combined with tight supplies has propelled uranium prices to a 12-year high, reaching $72 in September. A Rising Star Within the Booming Uranium Market As venture capitalists pour billions into nuclear startup projects, Katusa Research has uncovered a potential standout in the uranium market that could eclipse them all. Katusa Research just released an extensive report on Uranium Royalty Corp. (NASDAQ:UROY) (TSX:URC), an up and coming player in the uranium sector with substantial interests in some of the world's premier uranium mines. Uranium Royalty Corp stands out as the first company to embrace the royalty and streaming business model exclusively within the uranium sector. This move enabled the company to secure significant royalties on premier mines during a period when uranium prices were notably lower than present rates. Uranium Royalty ’s royalty model offers a unique advantage that allows the company to receive cash from mines it invests in for a lifetime, sharing in the success of profitable mines. The company has royalty interests in 18 projects that promise substantial cash flows, including Cameco's (NYSE:CCJ) McArthur River, which includes exceptionally high ore grades and licensed capacity, and Cigar Lake, which produced 14% of the world's uranium in 2022. Uranium Royalty Corp. (NASDAQ:UROY) (TSX:URC) maintains a possession of over 2 million pounds of physical uranium, acquired at an average price of $44.39 per pound. Given that the present price surpasses $70 per pound, the company has realized a gain of 70%. Furthermore, it holds no debt and boasts more than $138 million in liquidity. Behind Uranium Royalty is a team that’s a blend of experience and visionary zeal. President and CEO Scott Melbye is an industry expert with over 40 years in the uranium space including as President at Cameco and Amir Adnani, the President, CEO and founder of Uranium Energy Corp (NYSE-A:UEC). When you consider all of this, it comes as no surprise that large funds like Global X Uranium ETF and Sprott Uranium Miners are investing in Uranium Royalty Corp. For further details, click here to explore Katusa's comprehensive report on Uranium Royalty Corp. (NASDAQ:UROY) (TSX:URC) Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Katusa Research. Market Jar Media Inc. has or expects to receive from Katusa Research’s Digital Marketing Agency of Record (Native Ads Inc) one thousand one hundred USD for this article. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Katusa Research.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Katusa Research.’s industry; (b) market opportunity; (c) Katusa Research’s business plans and strategies; (d) services that Katusa Research intends to offer; (e) Katusa Researchs milestone projections and targets; (f) Katusa Research’s expectations regarding receipt of approval for regulatory applications; (g) Katusa Research’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Katusa Research’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Katusa Research’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Katusa Research’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Katusa Research’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Katusa Research’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Katusa Research to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Katusa Research’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Katusa Research’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Katusa Research’s business operations (e) Katusa Research may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Katusa Research undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Katusa Research nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Katusa Research nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Katusa Research or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Katusa Research or such entities and are not necessarily indicative of future performance of Katusa Research or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

October 05, 2023 08:30 AM Eastern Daylight Time

Image

All Industries

Minuteman Press Franchise Comes to Poundbury and Dorchester, Moves to Brand New Premises

Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update

Lithium Craze: Comparing Arianne Phosphate To Top Companies

Are You Trading With Or Against the Market Makers?

Interactive Strength Works To Sign Binding Acquisition Agreement That Would Transform The Digital Fitness Company Into A Profitable, High-Growth Business Across B2B and B2C Markets

How one fintech solution provider is bringing change to the volatile housing market in the U.K.

ToolsGroup Announces New User Interface for Enhanced User Experience and Supply Chain Performance

Navidar Advises Nova Hydraulics, Inc. in Its Sale to Motion & Control Enterprises

Big Tech is Going Nuclear to Power AI